Humira Biosimilar: Boehringer Faces Same Launch Hurdles As Amgen
Executive Summary
AbbVie seeks injunction against Boehringer Ingelheim's Cyltezo claiming infringement of 74 patents, 8 of which are in the initial round of litigation; as of Aug. 2, BI had not given 180-day launch notice.
You may also be interested in...
US Approvals Roundup: Cyltezo Biosimilar, Victoza CV Benefit, Gocovri In PD, Kedrab Rabies Biologic, Gout Combo Duzallo
FDA's clearances showcase the application of formulation technology to reduce problem side effects and improve convenience of available drugs.
Humira Biosimilar Interchangeability: The Race Begins
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.
Boehringer Ingelheim Limbering Up With Humira Biosimilar
Presenting equivalence data at EULAR for its biosimilar version of the world's best-selling drug, Humira, Boehringer Ingelheim is optimistic about its position in a crowded field. Karsten Kissel, head of global medical affairs biosimilars for the German group, spoke to Scrip.